LGVN vs. IVVD, BYSI, PLRX, ELUT, ORMP, QNCX, WHWK, CABA, MIST, and EPIX
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Invivyd (IVVD), BeyondSpring (BYSI), Pliant Therapeutics (PLRX), Elutia (ELUT), Oramed Pharmaceuticals (ORMP), Quince Therapeutics (QNCX), Whitehawk Therapeutics (WHWK), Cabaletta Bio (CABA), Milestone Pharmaceuticals (MIST), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical products" industry.
Longeveron vs. Its Competitors
Invivyd (NASDAQ:IVVD) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.
In the previous week, Invivyd had 1 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for Invivyd and 2 mentions for Longeveron. Longeveron's average media sentiment score of 0.94 beat Invivyd's score of 0.47 indicating that Longeveron is being referred to more favorably in the news media.
Invivyd has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.
Invivyd presently has a consensus target price of $5.85, indicating a potential upside of 645.22%. Longeveron has a consensus target price of $8.67, indicating a potential upside of 418.96%. Given Invivyd's higher possible upside, equities analysts plainly believe Invivyd is more favorable than Longeveron.
Longeveron has lower revenue, but higher earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
70.4% of Invivyd shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 25.4% of Invivyd shares are owned by company insiders. Comparatively, 11.2% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Invivyd has a net margin of -389.01% compared to Longeveron's net margin of -760.72%. Longeveron's return on equity of -85.07% beat Invivyd's return on equity.
Summary
Invivyd beats Longeveron on 8 of the 14 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
This page (NASDAQ:LGVN) was last updated on 7/27/2025 by MarketBeat.com Staff
